fda import alert semaglutide green list The "Green List" FDA launches "Green List" to

In the SURPASS and SURMOUNT trials, nausea was reported in up to 32% of participants, diarrhea in 23%, vomiting in 12%, and constipation in 11%

Research indicates that these drugs can lead to significant weight loss, with studies showing reductions ranging from 10% to 20%

RYBELSUS and OZEMPIC tablets are contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC tablets [see Adverse Reactions (6.2)]

Take one tablet per day or as directed by your physician

Enhances Workout Performance Ideal for cardio and training sessions

PMID 23674807 Pizzorno J